Blog

EHS Information

The imatinib mesylate tablets (Ruidaxin) independently developed by Kereit Pharmaceutical have obtained the drug registration certificate.

The imatinib mesylate tablets (Ruidaxin) independently developed by Kereit Pharmaceutical have obtained the drug registration certificate.

11

2025

/

03

The lenalidomide capsules (Rebif®) independently developed by Kereit Pharmaceutical have obtained the drug registration certificate.

The lenalidomide capsules (Rebif®) independently developed by Kereit Pharmaceutical have obtained the drug registration certificate.

22

2024

/

11

The hydrochloride erlotinib tablets (Rui Bikan®) independently developed by Kereit Pharmaceutical have obtained the drug registration certificate.

The hydrochloride erlotinib tablets (Rui Bikan®) independently developed by Kereit Pharmaceutical have obtained the drug registration certificate.

02

2025

/

01

Guangzhou Kereite Pharmaceutical's independently developed Ibrutinib capsules have made significant progress.

Guangzhou Kereite Pharmaceutical's independently developed Ibrutinib capsules have made significant progress.

18

2024

/

10

The application for listing of axitinib tablets independently developed by Guangzhou Keruite Pharmaceutical Co., Ltd. Pharmaceutical Co., Ltd. was accepted.

The application for listing of axitinib tablets independently developed by Guangzhou Keruite Pharmaceutical Co., Ltd. Pharmaceutical Co., Ltd. was accepted.

Guangzhou Keruite Pharmaceutical Co., Ltd. Pharmaceutical Co., Ltd. is a chemical pharmaceutical company located in Guangzhou, China, focusing on the field of anti-tumor drugs, hereinafter referred to as "Keruite Pharmaceutical".

18

2024

/

10

Cree's 2023 Outdoor League Building Annual Meeting Activities | Concentrate on Development and Strive for New Chapter

Cree's 2023 Outdoor League Building Annual Meeting Activities | Concentrate on Development and Strive for New Chapter

The New Year bell is about to ring. Through 2023, which is full of passion and vitality, we will welcome the brilliant sunshine of 2024.

25

2024

/

01

< 1 2 >

5

86020-8985 8964

8

E-mial

pvreport@bio-current.com

9

Tel

86020-8985 8964

Address: Room 803, Building B3, Science and Technology Enterprise Accelerator, No.11 Kaiyuan Avenue, Huangpu District, Guangzhou

Telephone:020-8985 8964

Production Base

Address: No.80, Spring Equinox Road, Huangpu District, Guangzhou

Telephone:020-8328 9091

Adverse Drug Reaction/Event Feedback E-mail:pvreport@bio-current.com

WeChat

Copyright©2024 All Rights Reserved of Guangzhou Keruite Pharmaceutical Co., Ltd.

Business License